Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$18.63
+0.5%
$16.37
$8.02
$19.08
$9.25B1.626.01 million shs7.48 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$24.53
-0.3%
$23.94
$13.45
$37.80
$2.15B0.121.16 million shs716,755 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$13.95
-0.9%
$11.86
$8.73
$14.48
$9.53B1.155.94 million shs6.72 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.37
-0.1%
$104.80
$27.54
$106.45
$9.17B0.142.17 million shs1.22 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+0.66%+3.04%+32.24%+27.97%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%-9.39%+1.15%+9.92%-34.30%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%+8.98%+18.82%+27.08%+17.92%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%+0.11%+1.10%+14.81%+257.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$18.63
+0.5%
$16.37
$8.02
$19.08
$9.25B1.626.01 million shs7.48 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$24.53
-0.3%
$23.94
$13.45
$37.80
$2.15B0.121.16 million shs716,755 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$13.95
-0.9%
$11.86
$8.73
$14.48
$9.53B1.155.94 million shs6.72 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.37
-0.1%
$104.80
$27.54
$106.45
$9.17B0.142.17 million shs1.22 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+0.66%+3.04%+32.24%+27.97%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%-9.39%+1.15%+9.92%-34.30%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%+8.98%+18.82%+27.08%+17.92%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%+0.11%+1.10%+14.81%+257.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.78
Moderate Buy$17.33-6.94% Downside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.81
Moderate Buy$42.8574.67% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.50
Strong Buy$17.6726.64% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.14
Hold$109.002.47% Upside

Current Analyst Ratings Breakdown

Latest IDYA, VRNA, ELAN, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/12/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$43.00 ➝ $44.00
9/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$36.00 ➝ $38.00
9/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$45.00
9/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/8/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOutperform$36.00
9/4/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuyOutperform
9/4/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Outperform$41.00
9/4/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$40.00
9/4/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$40.00
9/2/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweightBuy$16.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B2.08$2.27 per share8.22$12.33 per share1.51
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M307.12N/AN/A$12.25 per share2.00
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M327.92N/AN/A$7.45 per share1.87
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M216.84N/AN/A$2.56 per share41.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.8621.6620.933.449.68%7.04%3.45%11/6/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$0.99N/A3,545.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)

Latest IDYA, VRNA, ELAN, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989$0.26+$0.0611$0.02$1.19 billion$1.24 billion
8/6/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million
8/5/2025Q2 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.61
2.60
1.40
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
12.39
12.39
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
40.54
40.54
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.87
10.71
10.54
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.81 million492.39 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.64 million85.45 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860682.88 million609.13 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3086.19 million82.06 millionOptionable

Recent News About These Companies

Here’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$18.62 +0.10 (+0.51%)
Closing price 03:59 PM Eastern
Extended Trading
$18.65 +0.03 (+0.16%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$24.53 -0.08 (-0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$24.54 +0.02 (+0.06%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$13.95 -0.13 (-0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$13.88 -0.07 (-0.50%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$106.37 -0.06 (-0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$105.72 -0.65 (-0.61%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.